Screening of Investigational Therapeutics to Treat, Modify or Prevent Epilepsy for the NINDS Epilepsy Therapy Screening Program (ETSP)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH NIDA

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026R00040

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

AN12

Additional Details
Set Aside

NONE

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
The National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (NINDS), has issued a Sources Sought notice (Procurement Identifier: 75N98026R00040) to assess the availability and capabilities of qualified organizations to support the Epilepsy Therapy Screening Program (ETSP). This notice is for research and information-gathering purposes only and does not constitute a solicitation for proposals or quotations. **Purpose and Scope** The primary objective of this procurement is to identify organizations capable of conducting comprehensive preclinical pharmacological evaluations of investigational therapeutics aimed at treating, modifying, or preventing epilepsy and related disorders. The ETSP, formerly known as the Anticonvulsant Screening Program (ASP), is a longstanding initiative established in 1975 to address the critical need for new anti-seizure medications and to stimulate industry engagement in their clinical development. The program’s mission aligns with NINDS’s broader goal of advancing knowledge about the brain and nervous system to reduce the burden of neurological diseases. **Key Requirements and Objectives** The contractor will be responsible for a range of activities, including: - Conducting preclinical pharmacological evaluations of investigational compounds (small molecules, natural products, synthetic peptides, biologics, and potentially biomedical devices) using human-focused assays, in vivo tests, and in vitro assays. - Performing supporting pharmacokinetic studies to determine plasma and brain levels of investigational compounds in rodent models. - Adapting, developing, validating, and implementing new testing approaches as needed, including human-based research methods such as organoids, induced pluripotent stem cells (iPSCs), or human brain slices. - Ensuring the majority of work is performed by the prime contractor to maintain consistency, protect intellectual property, and manage controlled substances, though some domestic subcontracting may be permitted for specialized tasks. The contract will encompass three main performance areas: 1. **Established Workflow for Drug Resistant Epilepsy:** Implementation of acute and chronic seizure assays to evaluate investigational compounds for drug-resistant epilepsy. 2. **Models of Disease Prevention and Modification:** Use of models to identify compounds that can prevent epilepsy development or modify disease progression. 3. **Pharmacokinetic Studies:** Execution of pharmacokinetic testing in rats and mice to support compound evaluation. Ancillary studies may also be required, including models for epilepsy co-morbidities and supporting ADME (absorption, distribution, metabolism, and excretion) studies. **Compliance and Facility Requirements** - The contractor and any subcontractors must maintain full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International or an equivalent body. - An approved Animal Welfare Assurance from the NIH Office of Laboratory Animal Welfare (OLAW) is required for the duration of the contract. - All work must comply with the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals and be approved by the contractor’s Institutional Animal Care and Use Committee (IACUC). - The contractor must adhere to HHSAR clause 352.270(5)(b) regarding the care of live vertebrate animals, and promptly report any protocol violations. Additional requirements include ensuring the rigor, supply, and purity of investigational compounds, as well as robust data security, storage, access, and transfer protocols to NINDS. **Contract Structure and Duration** The anticipated period of performance includes a 12-month base period (from January 1, 2027, to December 31, 2027), with the possibility of up to nine additional 12-month option periods. The exact number of option periods will be specified in any future solicitation. **Contracting Entity and Classification** - **Contracting Entity:** National Institutes of Health, National Institute on Drug Abuse (NIDA) - **Location:** Bethesda, Maryland, United States - **NAICS Code:** 541715 – Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) - **Product Service Code:** AN12 - **Set-Aside:** None specified **Submission Instructions and Contact Information** Interested organizations, particularly small businesses, are encouraged to submit a capability statement that addresses each project requirement, including details on personnel qualifications, relevant contracts, and organizational information (UEI number, business type, NAICS code, etc.). Submissions must be in Microsoft Word or Adobe PDF format, not exceeding ten pages (excluding cover page, executive summary, and references), and must be sent electronically to the Contracting Officer, Rieka Plugge, at [email protected] by April 6, 2026, 9:00 A.M. Eastern Standard Time. **Special Considerations** - This is a market research notice only; no contract will be awarded as a result of this announcement. - Respondents should not submit proprietary, classified, or confidential information. - The government is not responsible for any costs incurred in responding to this notice. **Summary** This opportunity is ideal for organizations with demonstrated expertise in preclinical pharmacological research, animal model studies, and the development of innovative testing methodologies for neurological therapeutics. The successful contractor will play a critical role in advancing the discovery and development of new therapies for epilepsy, with a focus on drug-resistant forms and disease modification, in alignment with NINDS’s mission to reduce the burden of neurological disease. For further details and to access the official notice, visit: [SAM.gov Opportunity](https://sam.gov/opp/4705218c52e1476c8b7e22b16e97d670/view).